First-line test in suspected pheochromocytoma.
Quantitative Liquid Chromatography-Tandem Mass Spectrometry
New York DOH Approval Status
Drugs and medications may affect results and should be discontinued for at least 72 hours prior to specimen collection, if possible. Collection of the specimen after the patient has rested for 15 minutes in a supine position is recommended.
Lavender (EDTA), pink (K2EDTA), or green (sodium or lithium heparin).
Centrifuge within 1 hour. Transfer 2 mL plasma to an ARUP Standard Transport Tube and freeze immediately. (Min: 1 mL) Avoid hemolysis.
Frozen. Separate specimens must be submitted when multiple tests are ordered.
Plasma separator tubes. Body fluids other than EDTA or heparinized plasma. Non-frozen specimens. Grossly hemolyzed.
After separation from cells: Ambient: Unacceptable; Refrigerated: Unacceptable; Frozen: 1 month
Normetanephrine: 0.0-0.89 nmol/L
Metanephrine: 0.0-0.49 nmol/L
This test is useful in the detection of pheochromocytoma, a rare neuroendocrine tumor. The majority of patients with pheochromocytoma have a plasma normetanephrine concentration in excess of 2.2 nmol/L and/or a metanephrine concentration in excess of 1.1 nmol/L. Increased concentrations of these analytes serve as confirmation for diagnosis. Patients with essential hypertension and plasma concentrations of normetanephrine below 0.9 nmol/L and a metanephrine concentration below 0.5 nmol/L, can be excluded from further testing. If clinical suspicion remains, repeat testing or testing for metanephrines in a 24-hr. urine specimen should be considered.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
Laboratory Developed Test (LDT)
Isoetharine, isoproterenol, 3,4-methylenedioxyamphetamine (MDA), and 3,4-methylenedioxymethamphetamine (MDMA) are known to interfere with this test.
Many drugs/medications, including over-the-counter and herbal products, can interfere with test results. Testing for all potential interactions is not possible. If the patient is taking a drug not listed as an interferent, its potential effect on test results is unknown. If test results are inconsistent with clinical evidence, drug interference should be considered. If appropriate, the patient should discontinue the potential interferent for 48-72 hours and a new sample collected for retesting.
|Component Test Code*||Component Chart Name||LOINC|
- Fractionated metanephrines
- Fractionated Plasma Free Metanephrines
- Free Metanephrine
- Metanephrines, Fractionated
- NMN, plasma
- Normetanephrine, free
- Plasma Metanephrines
- Quantitative Metanephrines